Ketamine, a racemic mixture consisting of (S)-and (R)-ketamine, has been in clinical use
since 1970. Although best characterized for its dissociative anesthetic properties, ketamine …

Clinical studies have demonstrated that a single sub-anesthetic dose of the dissociative
anesthetic ketamine induces rapid and sustained antidepressant actions. Although this …

A revamped interest in the study of hallucinogens has recently emerged, especially with
regard to their potential application in the treatment of psychiatric disorders. In the last …

Depression is a common, devastating illness. Current pharmacotherapies help many
patients, but high rates of a partial response or no response, and the delayed onset of the …

Ketamine has rapid-onset antidepressant activity in patients with treatment-resistant major
depression (TRD). The safety and tolerability of racemic ketamine may be improved if given …

Pain is estimated to affect more than 20% of the global population, imposing incalculable
health and economic burdens. Effective pain management is crucial for individuals suffering …

The discovery of the antidepressant effects of ketamine has opened a breakthrough
opportunity to develop a truly novel class of safe, effective, and rapid-acting antidepressants …

Although the robust antidepressant effects of the N-methyl-d-aspartate receptor (NMDAR)
antagonist ketamine in patients with treatment-resistant depression are beyond doubt, the …

Therapeutic medications for the treatment of depression have serious limitations, particularly
delayed onset and low rates of efficacy. However, the discovery that a single subanesthetic …

Human studies examining the effects of the dissociative anesthetic ketamine as a model for
psychosis and as a rapidly acting antidepressant have spurred great interest in …